1. A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52). Issue 20 (25th June 2015) Authors: von Minckwitz, Gunter; Conrad, Bettina; Reimer, Toralf; Decker, Thomas; Eidtmann, Holger; Eiermann, Wolfgang; Hackmann, John; Möbus, Volker; Marmé, Frederik; Potenberg, Jochem; Stickeler, Elmar; Simon, Eike; Thomssen, Christoph; Huober, Jens; Denkert, Carsten; Alfer, Joachim; Jackisch, Christian;... Journal: Cancer Issue: Volume 121:Issue 20(2015) Page Start: 3639 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial. Issue 5 (May 2022) Authors: Nitz, Ulrike; Gluz, Oleg; Graeser, Monika; Christgen, Matthias; Kuemmel, Sherko; Grischke, Eva-Maria; Braun, Michael; Augustin, Doris; Potenberg, Jochem; Krauss, Katja; Schumacher, Claudia; Forstbauer, Helmut; Reimer, Toralf; Stefek, Andrea; Fischer, Hans Holger; Pelz, Enrico; zu Eulenburg, Chris... Journal: Lancet oncology Issue: Volume 23:Issue 5(2022) Page Start: 625 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12‐week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials. Issue 10 (11th February 2021) Authors: Graeser, Monika; Schrading, Simone; Gluz, Oleg; Strobel, Kevin; Würstlein, Rachel; Kümmel, Sherko; Schumacher, Claudia; Grischke, Eva‐Maria; Forstbauer, Helmut; Braun, Michael; Christgen, Matthias; Adams, Jascha; Nitzsche, Henrik; Just, Marianne; Fischer, Hans Holger; Aktas, Bahriye; Potenberg, J... Journal: International journal of cancer Issue: Volume 148:Issue 10(2021) Page Start: 2614 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Issue 9 (September 2018) Authors: Chekerov, Radoslav; Hilpert, Felix; Mahner, Sven; El-Balat, Ahmed; Harter, Philipp; De Gregorio, Nikolaus; Fridrich, Claudius; Markmann, Susanne; Potenberg, Jochem; Lorenz, Ralf; Oskay-Oezcelik, Guelten; Schmidt, Marcus; Krabisch, Petra; Lueck, Hans-Joachim; Richter, Rolf; Braicu, Elena Ioana; du... Journal: Lancet oncology Issue: Volume 19:Issue 9(2018) Page Start: 1247 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials. (October 2021) Authors: Graeser, Monika; Harbeck, Nadia; Gluz, Oleg; Würstlein, Rachel; zu Eulenburg, Christine; Schumacher, Claudia; Grischke, Eva-Maria; Forstbauer, Helmut; Dimpfl, Moritz; Braun, Michael; Christgen, Matthias; Kreipe, Hans Heinrich; Potenberg, Jochem; von Schumann, Raquel; Aktas, Bahriye; Kolberg-Liedt... Journal: Breast Issue: Volume 59(2021) Page Start: 58 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗